PGRN-8310, RCFB58 c3.7, RCi200, PGRN8310
LUBi001-C
General
Cell Line |
|
| hPSCreg name | LUBi001-C |
| Cite as: | LUBi001-C (RRID:CVCL_II99) |
| Alternative name(s) |
PGRN-8310, RCFB58 c3.7, RCi200, PGRN8310
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines |
LUBi001-A (PGRN-8310, PGRN8310, RCi195, RCFB58 c12.5) Donor's gene variants: GRN, GRN, GRN, GRN Donor diseases: Frontotemporal dementia LUBi001-B (PGRN-8310, RCFB58 c4.4, PGRN8310, RCi194) Donor's gene variants: GRN, GRN, GRN, GRN Donor diseases: Frontotemporal dementia UCLi004-A (RCi173, RCFB60c6) Donor's gene variants: C9orf72, C9orf72 Donor diseases: Amyotrophic lateral sclerosis Frontotemporal dementia UCLi004-B (RCFB60c7, RCi177) Donor's gene variants: C9orf72, C9orf72 Donor diseases: Amyotrophic lateral sclerosis Frontotemporal dementia UCLi004-C (RCi172, RCFB60c2) Donor's gene variants: C9orf72, C9orf72 Donor diseases: Amyotrophic lateral sclerosis Frontotemporal dementia UCLi002-A (HHItC9D-V34, DN19) Donor's gene variants: C9orf72, C9orf72 Donor diseases: Frontotemporal dementia |
| Last update | 2nd July 2019 |
| User feedback | |
Provider |
|
| Generator | H. Lundbeck A/S (LUB) |
| Distributors | |
External Databases |
|
| BioSamples | SAMEA4309665 |
| Cellosaurus | CVCL_II99 |
| Wikidata | Q54903227 |
General Information |
|
| Projects | |
| * Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: allowed
Commercial use: allowed
|
Donor Information
General Donor Information |
|
| Sex | male |
| Age of donor (at collection) | 65-69 |
Phenotype and Disease related information (Donor) |
|
| Diseases | A disease was diagnosed.
|
Donor Relations |
|
| Other cell lines of this donor | |
External Databases (Donor) |
|
| BioSamples | SAMEA4096476 |
Ethics
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
| Was the consent voluntarily given? | Yes |
| Has the donor been informed that participation will not directly influence their personal treatment? | No |
| Can you provide us with a copy of the Donor Information Sheet provided to the donor? | Yes |
| Do you (Depositor/Provider) hold the original Donor Consent Form? | No |
| If you do not hold the Donor Consent Form, do you know who does? | Yes |
| Is there other documentation provided to the donor for consenting purposes? | Yes |
| Confirm that consent was obtained by a qualified professional | Yes |
| Has the donor agreed to be re-contacted? | No |
| Has the donor been informed about how her/his data will be protected? | Yes |
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | pseudonymised |
| Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
| * Does consent expressly prevent the derivation of pluripotent stem cells? | No |
| * Does consent pertain to a specific research project? | No |
| Does consent permit unforeseen future research, without further consent? | Yes |
| Does the consent permit uses of donated embryo/tissue or derived cell line intended for clinical treatment or human applications? | No |
| Does consent expressly prevent development of commercial products? | No |
| Does consent expressly prevent financial gain from any use of the donated embryo/tissue, including any product made from it? | No |
| Does consent expressly permit storage of donated embryo/tissue for an unlimited time? | Yes |
| Does consent prevent the DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
| Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
Does consent permit research by | |
| an academic institution? | Yes |
| a public organisation? | Yes |
| a non-profit company? | Yes |
| a for-profit corporation? | Yes |
| Does consent expressly permit collection of genetic information? | Yes |
| Has the donor been informed that their donated biosample or derived cells may be tested for the presence of microbiological agents / pathogens? | Yes |
| How may genetic information associated with the cell line be accessed? | Open Access |
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
| Does the consent permit the donor, upon withdrawal of consent, to stop the use of the derived cell line(s) that have already been created from donated samples? | No |
| Does the consent permit the donor, upon withdrawal of consent, to stop delivery or use of information and data about the donor? | No |
| Does consent permit access to medical records of the donor? | No |
| Does consent permit access to any other source of information about the clinical treatment or health of the donor? | No |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
| Name of accrediting authority involved? | Institute of Neurology Joint Research Ethics Committee |
| Approval number | 09/H0716/64 |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? | Yes |
| Name of accrediting authority involved? | Institute of Neurology Joint Research Ethics Committee |
| Approval number | 09/H0716/64 |
| Do you have obligations to third parties in regard to the use of the cell line? | No |
| Are you aware of any further constraints on the use of the donated embryo/tissue or derived cells? | No |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? | |
hIPSC Derivation
General |
|
| Source cell type |
A connective tissue cell which secretes an extracellular matrix rich in collagen and other macromolecules. Flattened and irregular in outline with branching processes; appear fusiform or spindle-shaped.; These cells may be vimentin-positive, fibronectin-positive, fsp1-positive, MMP-1-positive, collagen I-positive, collagen III-positive, and alpha-SMA-negative.
|
| Age of donor (at collection) | 65-69 |
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Sendai virus |
| Genes | |
Vector free reprogramming |
|
Other |
|
| Derived under xeno-free conditions |
No |
| Derived under GMP? |
No |
| Available as clinical grade? |
No |
Culture Conditions
| Surface coating | Matrigel/Geltrex |
| Feeder cells |
No |
| Passage method |
Enzyme-free cell dissociation
EDTA
|
| O2 Concentration | 21 % |
| CO2 Concentration | 5 % |
| Medium |
Essential 8™
|
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| SSEA-1 |
No |
|
||||
| SSEA-4 |
Yes |
|
||||
| TRA 1-60 |
Yes |
|
Differentiation Potency
Microbiology / Virus Screening |
|
| HIV 1 | Negative |
| HIV 2 | Negative |
| Hepatitis B | Negative |
| Hepatitis C | Negative |
| Mycoplasma | Negative |
Certificate of Analysis |
|
| Is there a certificate of analysis available? |
Yes
Passage:
17
|
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
46,XY
Passage number: 18
Karyotyping method:
G-Banding
|
Other Genotyping (Cell Line) |
|
Login to share your feedback, experiences or results with the research community.